产品详情
简单介绍：
Anti-KIAA1704抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-KIAA1704抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-KIAA1704
Cat. Number:
Anti-KIAA1704抗体KL-17023R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
KIAA1704 is a 340 amino acid protein that is encoded by a gene which maps to chromosome 13. Comprising nearly 4% of human DNA, chromosome 13 contains around 114 million base pairs and 400 genes. Key tumor
Anti-KIAA1704抗体suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. RB1 encodes a crucial tumor suppressor protein which, when defective, leads to malignant growth in the retina and has been implicated in a variety of other cancers. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival. Trisomy 13, also known as Patau syndrome, is quite deadly and the few who survive past one year suffer from permanent neurologic defects, difficulty eating and vulnerability to serious respiratory infections. There are four isoforms of KIAA1704 that are produced as a result of alternative splicing events.
Also known as:
AD029; BA245H20.2;
Anti-KIAA1704抗体Hypothetical protein LOC55425; K1704_HUMAN; Kiaa1704; Lipopolysaccharide specific response-7 protein; Lipopolysaccharide-specific response protein 7; LSR7; RP11 245H20.2; Uncharacterized protein KIAA1704.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Horse, .
●
Immunogen: KLH conjugated
Anti-KIAA1704抗体synthetic peptide derived from human KIAA1704.
●
Predicted Molecular Weight: 38kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Anti-KIAA1704抗体
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
